Technology

CORESTEMCHEMON: “FDA Confirms Approval of Phase 3b Protocol for New ALS Drug ‘NeuronaTa-Al’”

Received Official Meeting Minutes… Moving Forward with U.S. Approval Following Additional Confirmatory Clinical Trials Existing safety data can be utilized… Detailed design to be determined through subsequent discussions

NA EUN-KYUNG
2026-11-16 18:14:02
[Edaily Reporter NA EUN-KYUNG ] CORESTEMCHEMON(166480)has received approval from the U.S. Food and Drug Administration (FDA) regarding its plan to proceed with an additional Phase 3b clinical trial for its Lou Gehrig’s disease treatment, “NeuronaTa-R.” With the written confirmation of last month’s discussions, the path toward applying for U.S. approval following the additional clinical trial has been finalized.

CORESTEMCHEMON announced on the 16th that it had received the official minutes of the FDA’s Type C meeting regarding “NeuronaTa-R,” a stem cell therapy for ALS (amyotrophic lateral sclerosis).

CORESTEMCHEMON’s ALS stem cell therapy “NeuronaTa-R” (Photo: CORESTEMCHEMON)


CORESTEMCHEMON held a Type C meeting with the FDA on the 17th of last month. At that time, the FDA expressed the view that it would be reasonable to validate the therapeutic effects observed in previous clinical trials through a new clinical trial. Based on this, the company previously announced its plan to proceed with a follow-up Phase 3b trial.

The minutes of this meeting confirmed that the FDA agreed to a development pathway involving efficacy validation through a new Phase 3b clinical trial, followed by a Biologics License Application (BLA). This approach prioritizes demonstrating therapeutic efficacy in an additional confirmatory clinical trial rather than applying for approval based solely on existing clinical data.

NeuronaTa-R is a therapy that uses mesenchymal stem cells harvested from the patient’s own bone marrow and received conditional approval in South Korea in 2014. However, in the Phase 3 clinical trial completed in 2024, it failed to achieve statistical significance in the primary efficacy endpoint for the overall patient population. Since then, the company has been pursuing additional clinical trials based on the therapeutic effects observed in certain patient subgroups.

The new Phase 3b trial is scheduled to be conducted as a randomized, double-blind, placebo-controlled study. The company proposed the change in the total score on the ALS Functional Rating Scale-Revised (ALSFRS-R) at Week 24, compared to baseline, as the primary efficacy endpoint. The FDA did not raise any major objections to this basic approach and agreed to discuss the specific clinical design in a subsequent Type D meeting.

It was also confirmed that safety data obtained from previous clinical trials can be utilized in the U.S. approval review. Based on the previous Phase 2 and Phase 3 trials, as well as real-world data (RWD), the FDA positively assessed the safety profile of Neuronata-R. The agency also agreed to the company’s plan to combine the safety results from the new Phase 3b trial with the existing data and submit them in the Biologics License Application (BLA).

CORESTEMCHEMON plans to conduct the Phase 3b trial in South Korea, just as it did with the previous Phase 3 trial. The FDA indicated that clinical results obtained in South Korea could be used in the U.S. approval review process, provided they meet the guidelines of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and other relevant standards. The company plans to simultaneously submit applications for clinical trial approval to regulatory authorities in both South Korea and the United States.

However, discussions regarding the detailed clinical design and manufacturing and quality control (CMC) remain pending. The FDA stated that it has no objection to further exploring the association between neurofilament light chain (NfL)—a marker of nerve damage—and clinical outcomes, but specific analytical methods require follow-up discussions. Comparative equivalence data resulting from a change in manufacturing sites and issues related to changes in shelf life are also subjects for further discussion.

These meeting minutes confirm the development direction for U.S. approval; however, neither the Phase 3b trial plan nor the marketing authorization itself has been approved. The key issue going forward is whether the new clinical trial will be able to overcome the failure to demonstrate efficacy in previous trials.

Yang Gil-an, CEO of CORESTEMCHEMON, stated, “Receiving these meeting minutes has clarified the path toward U.S. approval via a Phase 3b confirmatory clinical trial,” adding, “We will finalize the clinical trial design in subsequent meetings and proceed with the submission of additional CMC data without delay.”

Economy

Corporation

IT·Science

Economy

LG Innotek Develops Communication Module for Smart Home Cameras… Expanding Beyond Vehicles to Home Appliances

LG Innotek has developed an ultra-compact communication module for smart home cameras that integrates Wi-Fi, Bluetooth, and Thread into a single unit. As the company expands its technological capabili…
2026-11-16 17:41:35

Corporation

OTOKI’s 3Q Operating Profit Falls 34.5%, but… Overseas Sales Show Double-Digit Growth

OTOKI has succeeded in increasing its revenue, driven by strong sales of instant noodles and sauces and rapid overseas growth, despite deteriorating profitability in the domestic market.Ottogi(007310)…
2026-11-16 18:07:59

IT·Science

CORESTEMCHEMON: “FDA Confirms Approval of Phase 3b Protocol for New ALS Drug ‘NeuronaTa-Al’”

CORESTEMCHEMON(166480)has received approval from the U.S. Food and Drug Administration (FDA) regarding its plan to proceed with an additional Phase 3b clinical trial for its Lou Gehrig’s disease treat…
2026-11-16 18:14:02